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Abstract 
The objective of the study is to evaluate the levels of IL-6 and TNF-α in sera of patients with type 1 diabetes 
mellitus (T1DM) compared to healthy people and correlate their levels with different factors. The results 
showed significant increase in the levels of IL-6 and TNF-α (P≤0.05) in T1DM compared to control group. The 
levels of IL-6 were not significant when compared with age groups, duration of the disease and level of HbA1c. 
On contrast the levels of TNF-α in T1DM patients was significantly increased (P≤0.05) when compared with 
age groups and duration of the disease but not significantly with different HbA1c. 
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1. Introduction 
Type 1 diabetes mellitus (T1DM) is considered as chronic inflammatory disease of pancreatic islets. It occurs as 
a result of destruction of beta cells of Langerhans which is responsible for insulin production. This destruction is 
due to autoantibodies, cytotoxic T cells and inflammatory mediators [1,2]. T1DM represents about 5-10% of 
diabetic cases and influences children and teenagers [3]. Cytokines are extracellular protein of low molecular 
weight serve as mediator of the immune response. They induce beta cells damage in human T1DM via 
generation of  NO [4].  
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IL-6 and TNF-α mediated damage to macrovascular tissues, altered insulin secretion and glucose homeostasis 
[5,6]. IL-6 and TNF-α are adipocyte secreting factors and their injection induce an increase in concentration of 
triglycerides and low density lipoprotein [7]. Cytokines may play important roles in the pathogenesis of T1DM 
and they are also regarded as markers of inflammatory response [8,9].The present study involves detection of 
IL-6 and TNF-α In T1DM patients in Mosul  and correlates their concentrations with different factors. 
2. Materials and Methods 
2.1. Subject group 
This study was carried out on 90 patients with T1DM  (35 males and 55 females)  and healthy control group (25 
individual) with age range between 1-25 years. Data was obtained from subject group and control which include 
age, sex, duration of the disease, type of therapy, complications, family history of diabetes and residence. 
2.2. Blood and serum collection 
Five ml of venous blood was withdrawn from each patient and control subjects . One ml of blood was put in 
EDTA tube and the remaining blood samples were left to clot in a plain tube at 37˚C for 30 minutes, centrifuged 
at 3000 rpm for 5 minutes, and serum was separated and dispensed in 0.5 ml Eppendorf tubes and stored at -
20˚C for subsequent specific laboratory investigations. 
2.3. Serological and Chemical Tests 
 Elisa test was used to detect the concentration of  IL-6 and TNF-α in serum. They were supplied by Wuhan 
Cundu Biological Company (China). The test is based on interaction between monoclonal antibodies against IL-
6 and TNF-α which are coated in the microtiter plates with antigens in the serum. The interaction is detected by 
addition of HRP resulting in changing the color that can be read by Elisa reader at 450 nm (Rt-2100c microplate 
reader. The procedure of Elisa was done according to manufacturer instructions and the results were expressed 
in pg/ml .HbA1C depends on the measurement of hemoglobin in RBCs which carry sugar. In this test whole 
blood was used and the test was carried out according to the manufacturer instructions using On. Call. A1C 
Analyzer and kits (Acon. USA). And the results were expressed in percentages. 
2.4. Statistical Analysis 
The results were analyzed using SPSS. Results are expressed as mean ± standard deviation. Student t-test was 
used to compare between two groups, P≤0.05 was considered statistically significant. Linear regression analysis 
was used to study the correlation between parameters. 
3. Results 
The results of IL-6 levels in sera of T1DM patients  showed clear increase (8.248 pg/ml) which is statistically 
significant (P≤0.05)  when compared with control group which was 1.392 pg/ml (Table 1).  
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Table 1: Mean, standard deviation and correlation of IL-6 between type 1 diabetic mellitus. 
P 
   
T - Value P  
 
Correlation 
   
SE of Mean St.D Mean IL-6 
0.000 16.192** 0.774 0.074 
0.294 2.636 8.248 T1DM 
0.303 1.253 1.392 Control 
 
IL-6 in T1DM when compared with different age groups showed no significant differences . The highest 
concentration of IL-6 was in age group >16 years (9.04 pg/ml) and the lowest (6.61 pg/ml) was in age group <5 
years (Figure 1).  
 
Figure 1: IL-6 and TNF-α levels in relation to age groups of type 1 diabetes mellitus 
The correlation between IL-6 and duration of the disease, HbA1C,  showed weak positive but not significant 
(Figures 2,3).  
High level of IL-6 was observed when the duration of the disease was >7 years (9.03 pg/ml) and the lowest level 
at <5 years (6.61 pg/ml). Also high level of IL-6 was noticed at 14-17% HbA1C.  
The result of TNF-α  in T1DM patients is statistically significant (P≤0.05) compared with control group (Table 
2).  
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Table 2: Table 1. Mean, standard deviation and correlation of TNF-α between type 1 diabetic mellitus. 
P 
T - Value T - Value P r Correlation 
Correlation 
( r ) SE of Mean St.D Mean TNF- α 
0.000 16.955** 0.952 0.016 
0.828 2.847 16.371 T1DM  
0.762 2.951 2.472 Control 
 
The mean of TNF-α levels in T1DM was 16.371 pg/ml which is higher than control group (2.472 pg/ml). Also 
positive correlation statistically significant (P≤0.05) was noticed with  age groups and duration of the diseases 
(Figures 1,2), while no correlation exists with HbA1C (Figure 3).  
 
Figure 2: IL-6 and TNF-α levels in relation to duration of  type 1 diabetes mellitus 
 
Figure 3: 1. IL-6 and TNF-α levels in relation to HbA1C in type 1 diabetes mellitus 
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The highest level of  TNF-α was in age group >16 years (17.43 pg/ml) and the lowest was at age group <5 years 
14.48. Also the highest level of TNF-α was observed at duration of the disease >7 years (17.76 pg/ml) and the 
lowest were at < 4 years (15.35 pg/ml).  
4. Discussion 
Cytokines play central role in the inflammatory process through regulation of leukocytes migration to damaged 
tissues [7]. Cytokines stimulate destruction of beta cells in diabetic patients through generation  of NO [4].  
  IL-6 and TNF-α were selected as markers of inflammatory process as they alter insulin secretion through direct 
or through stimulation of free fatty acid production and altered glucose homeostasis [9]. IL-6 is important factor 
in the immune system and has important role in glucose metabolism [10,11]. Many studies showed the effect of 
IL-6 on secretion of insulin [12-15]. Cytokines have also a role in the development of cardiovascular disease 
[16].The current study showed significant increase of IL-6 mean in T1DM patients compared to control group. 
Its level increased with duration of  the disease and age groups but not significant similar finding observed by 
others [17]. However, in some studies  the level of IL-6 was high at beginning of the disease compared to those 
of  long duration [18]. Other studies showed no difference in IL-6 [7,19] or even decreased [10]. There is a 
positive correlation between IL-6 and HbA1C but not significant, similar finding was observed [21]. This could 
be explained that hyperglycemia stimulates the monocytes to secrete high level of IL-6 [22]  TNF-α stimulates 
macrophages and its level increases with duration of diabetes as well as physiological control of vascular 
adhesion molecules [23]. In this study, TNF-α was statistically significant in T1DM patients compared to 
control group as well as  positive correlation with age groups and durations of the disease. Similar findings 
showed by others [24]. High level of TNF-α in all age groups and durations indicates persistent activation of 
immune inflammatory response [7]. However some studies showed increased level of TNF-α  in early stage of 
the disease [7,25]. On contrast, other studies showed no change in the level of TNF-α during early and late 
stages of the disease [ 26].  No correlation was observed between TNF-α and HbA1C. 
5. Conclusion 
IL-6 and TNF-α were increased significantly in T1DM patients compared to control group and their correlations 
with HbA1C, age groups and duration of the disease  were variable  
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